You are on page 1of 2

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new sciences promise by bringing novel medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen is committed to advancing science to dramatically improve peoples lives.

To serve patients

Headquarters Thousand Oaks, California Staff Approximately 17,000 worldwide Stock Listing NASDAQ: AMGN Chairman and CEO Kevin W. Sharer 2008 Financial Highlights Total revenue: $15.0 billion Product sales: $14.7 billion R&D investment: $2.9 billion Address/Phone One Amgen Center Drive Thousand Oaks, CA 91320-1799 Main: (805) 447-1000 Investors: (805) 447-1060

Reaching Patients Worldwide

Amgen medicines help patients around the world. The company has facilities or subsidiaries in the following locations: United States (including Puerto Rico) California (Fremont, South San Francisco, Thousand Oaks) Colorado (Boulder, Longmont) Kentucky (Louisville) Massachusetts (Cambridge) Puerto Rico (Juncos) Rhode Island (West Greenwich) Washington (Bothell, Seattle) Washington, D.C. Outside the United States Australia Finland Austria France Belgium Germany Brazil Greece Canada Hong Kong Czech Republic Hungary Denmark India England Ireland Estonia Italy Japan Latvia Lithuania Luxembourg Mexico The Netherlands Norway Poland Portugal Russia Slovakia Slovenia Spain Sweden Switzerland United Arab Emirates

Aranesp (darbepoetin alfa) Enbrel (etanercept) EPOGEN (Epoetin alfa) Neulasta (pegfilgrastim) NEUPOGEN (Filgrastim) Nplate (romiplostim) Sensipar (cinacalcet) Vectibix (panitumumab) For product information, including important safety information, visit

Last Updated August 11, 2009 | Page 1


An Interdisciplinary Approach to R&D

Kevin W. Sharer Chairman of the Board, Chief Executive Officer and President David W. Beier Senior Vice President, Global Government and Corporate Affairs Fabrizio Bonanni Executive Vice President, Operations Robert A. Bradway Executive Vice President and Chief Financial Officer Thomas J. Flanagan Senior Vice President and Chief Information Officer Brian M. McNamee Senior Vice President, Human Resources George J. Morrow Executive Vice President, Global Commercial Operations Roger M. Perlmutter Executive Vice President, Research and Development Anna S. Richo Senior Vice President and Chief Compliance Officer David J. Scott Senior Vice President, General Counsel and Secretary

For more than 25 years, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. We focus on pioneering treatments for serious illness. Our R&D organization has cultivated expertise in multiple treatment modalitieslarge-molecule proteins, small molecules and antibodiesallowing us to choose the best target for attacking disease and to use the modality most likely to affect that target. Our research facilities are located in South San Francisco and Thousand Oaks, California; Cambridge, Massachusetts; Seattle, Washington; Burnaby, British Columbia, Canada; and Regensburg, Germany.

A Pioneer in Biotechnology Manufacturing

Assuring that Amgen medicines rapidly, reliably and safely reach patients is the charge of Amgens manufacturing, process development, quality and distribution teams. Manufacturing therapies based on proteins found in the human body is a complex and highly specialized activity. From process development and clinical manufacturing to full-scale therapeutic protein production, Amgen has built one of the industrys largest and most reliable operations. Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington and Puerto Rico.

Advancing Science through Strategic Partnerships

With more than 100 active collaborations, Amgen is well-suited to be a partner of choice in the human therapeutics business. With the capabilities and financial strength of a large company, Amgen can offer partners the resources to support a potential new medicine as it advances from lab to clinic to marketplace. At the same time, Amgen retains the agility and decisiveness of a smaller biotech, with an unwavering commitment to science and patients.

Philanthropy That Makes a Positive Difference

The causes Amgen supports, through the Amgen Foundation and other channels, reflect the companys efforts to elevate science, help patients and improve lives. The Amgen Foundation Since its founding in 1991, the Amgen Foundation has contributed nearly $110 million to regional and national nonprofit groups that advance science education, improve quality of care and access for patients, and support vital community resources. The Foundation also matches Amgen staff member donations to eligible organizations. Science Education Amgen is inspiring and preparing the scientists of tomorrow through several signature science education programs, including Amgen Scholars, an eight-year, $27.5 million program for college undergraduates; the Teach for America Amgen Fellows Program; the Amgen Bruce Wallace Biotechnology Lab Program; and the Amgen Award for Science Teaching Excellence. Community Involvement In the communities in which Amgen staff live and work, the company commits millions of dollars in charitable donations, and staff members devote thousands of hours of personal time, to programs and services that can make meaningful differences in peoples lives.


This fact sheet is a summary of more detailed disclosure that can be found in Amgens filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forwardlooking statements that involve significant risks and uncertainties, discussion of which can be found in Amgens most recent Forms 10-K, 10-Q, and 8-K and on The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.
Last Updated August 11, 2009 | Page 2